Highest-materiality recent filing
CG Oncology stockholders elect two Class II directors, ratify auditor at 2026 annual meeting
Christina Rossi elected with 67,531,501 shares for (99.87% of votes cast); Victor Tong Jr. elected with 62,401,874 shares for.
CG Oncology President & COO Bellete to depart June 30; CEO Kuan becomes President
Ambaw Bellete, President & COO, agreed to separation effective June 30, 2026; severance per existing employment agreement.
CG Oncology Q1 net loss widens to $60.2M; BLA submission on track for Q4 2026
Net loss of $60.2M ($0.71 per share) vs $34.5M ($0.45) in Q1 2025.
CG Oncology appoints Jim DeTore as CFO with $520K base and $5M equity
Jim DeTore, age 61, appointed CFO effective April 13, 2026; previously served as interim principal financial officer since Nov 2025.
CG Oncology reports FY2025 net loss $161M; cash $903M provides runway to 1H 2029
Q4 2025 net loss $41.3M ($0.52/share) vs $31.8M ($0.46/share) in Q4 2024.
CG Oncology ups ATM equity offering capacity by $300M to $550M
Filing increases aggregate offering of common stock under Open Market Sale Agreement from $250M to $550M.
PIVOT-006 topline data for cretostimogene in intermediate-risk NMIBC now expected in first half of 2026, nearly one year ahead of schedule.
CG Oncology appoints Christina Rossi to board; director Simone Song resigns
Christina Rossi appointed to Board as Class II director effective November 24, 2025.
CG Oncology Q3 net loss $43.8M ($0.57/share); initiates BLA for cretostimogene
Net loss of $43.8M ($0.57 per share) for Q3 2025 vs $20.4M ($0.30) in Q3 2024.
CG Oncology CFO Robert Lapetina resigns; Jim DeTore named interim CFO effective Nov 17, 2025
Robert Lapetina resigned as interim principal financial and accounting officer, effective Nov 30, 2025.
The filing references a corporate presentation (Exhibit 99.1) provided at the Sept 9, 2025 Morgan Stanley conference.
CG Oncology reports 41.8% 24-month CR in Phase 3 BOND-003 for cretostimogene
24-month CR rate of 41.8% (46/110) in BCG-unresponsive HR NMIBC; 12 additional CRs since April 2025 AUA.
CG Oncology Q2 net loss $41.4M; jury kills ANI royalties; BOND-003 75.5% CR
Net loss $41.4M ($0.54/sh) vs $18.9M ($0.28/sh) year ago; R&D $31.3M, G&A $17.4M.
CFO Corleen Roche resigns effective Aug 5; Robert Lapetina named interim principal financial officer
CFO Corleen Roche resigns effective August 5, 2025.
CG Oncology stockholders elect three Class I directors, ratify EY as auditor at 2025 annual meeting
Arthur Kuan, James J. Mulé, Leonard Post elected as Class I directors to serve until 2028 annual meeting.
CG Oncology Q1 net loss $34.5M; BLA submission on track for H2 2025
Net loss of $34.5M ($0.45/share) vs $16.9M ($0.36) a year ago; R&D spend rose to $27.5M.
CG Oncology reports 42.3% 24-month CR rate in BOND-003; 97.3% progression-free at 24 mo
BOND-003 Cohort C: 75.5% complete response (CR) at any time; 42.3% 24-month CR by K-M estimate.
CG Oncology reports FY2024 net loss $88.0M; cash $742M; cretostimogene CR rate 75.5%
Net loss attributable to common stockholders $88.0M ($1.41/share) vs $67.8M ($15.65/share) in FY2023.
83 of 110 patients (75.5%) achieved complete response at any time in BOND-003 for BCG-unresponsive NMIBC with CIS.
CEO Arthur Kuan and President/COO Ambaw Bellete: 1.5x salary + prorated bonus outside CIC; 2.0x salary + full bonus inside CIC.
CG Oncology reports 74.5% CR rate in Phase 3 BOND-003; median DOR >27 months
74.5% (82/110) achieved complete response at any time (95% CI 65.4-82.4%).
CG Oncology Q3 net loss $20.4M; cash $540.7M, runway through 2027
Net loss of $20.4M ($0.30 per share) vs $17.5M ($4.00) in Q3 2023.
Net loss of $18.9M ($0.28 EPS) vs $11.6M loss ($3.93 EPS) in Q2 2023; R&D spend $18.5M vs $9.8M YoY.
CG Oncology reports 54% CR at 24 months for cretostimogene combo in NMIBC
Phase 2 CORE-001 final results: 54% (19/35) complete response rate at 24 months in BCG-unresponsive HR-NMIBC with CIS.
Net loss $16.9M ($0.36/sh) in Q1 2024 vs $12.4M ($3.22/sh) Q1 2023; R&D expense $17.2M (up from $7.8M).
CG Oncology Phase 3 BOND-003: cretostimogene achieves 75.2% complete response in high-risk NMIBC
75.2% complete response (79/105 patients; 95% CI: 65-83) at any time in BCG-unresponsive high-risk NMIBC.
CG Oncology discloses 2023 executive bonuses in amended summary comp table
CEO Arthur Kuan awarded $189,000 performance bonus for 2023; total comp $3.93M.
CG Oncology completes IPO of 23M shares at $19.00, raising $437M gross
IPO closed on Jan 29, 2024: 23M shares (includes full exercise of underwriters' option for 3M additional shares) at $19.00/share.
On May 20, 2026, the Company’s Board of Directors also approved the appointment of Arthur Kuan as President of the Company, in addition to his other positions, in connection with Mr. Bellete’s separation.
On May 20, 2026, CG Oncology, Inc. (the “ Company ”) and Ambaw Bellete, the Company’s President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026.
Max materiality 0.85 · Median 0.68 · Most common event other_material